Management of MEN1 Related Non-Functioning Pancreatic NETs: A Shifting Paradigm. Results from the Dutch MEN1 Study Group Abstract #1765

Introduction: The evidence base when to operate MEN1 related non-functioning pancreatic neuroendocrine tumors (NF-pNETs) is meager.
Aim(s): To assess if surgery for MEN1 related NF-pNETs is effective for improving overall survival and preventing liver metastasis.
Materials and methods: MEN1 Patients diagnosed with NF-pNETs between 1990-2014 were selected from the DutchMEN1 study group database, including >90% of the Dutch MEN1 population. The effect of surgery was estimated using time-dependent Cox analysis with propensity score restriction and adjustment.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Drs. Sjoerd Nell
Keywords: MEN1

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1769 Minimal Risk of Persistent or Recurrent Hypoglycemia after MEN1-Related Insulinoma Surgery. A Large International Cohort Study
Introduction: Current literature states that 15-30% of the MEN1 patients suffer from hypoglycemia after insulinoma surgery.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Drs. Sjoerd Nell
Keywords: MEN1
#1438 An Unusual Phenotype of Multiple Endocrine Neoplasia Type 1 with a Small Intestine Neuroendocrine Tumor Associated with Large Deletion of the MEN1 Gene
Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant inherited tumor syndrome that is caused by germline mutations in the Menin suppressor gene on chromosome 11q13. Small intestine neuroendocrine neoplasias (SI-NEN) are currently not considered to be part of the phenotype of the MEN1-syndrome.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: MD Jerena Manoharan
#1858 Quality of Life in Patients with Multiple Endocrine Neoplasia Type I (MEN1): Results from the Dutch MEN1 Study Group
Introduction: Multiple Endocrine neoplasia type 1 (MEN1) is a hereditary tumor syndrome, characterized by an increased lifetime risk of benign and malignant endocrine tumors in various organs. Data on quality of life (QoL) in patients with MEN1 are scarce, whereas QoL is considered an important treatment outcome.
Conference: 14th Annual ENETS conference (2017)
Category: ...none of the above
Presenting Author: MD Rachel van Leeuwaarde
Keywords: MEN1, QoL
#901 Impact of Long-Acting Octreotide in Patients with Early-Stage MEN1-Related Duodeno-Pancreatic Neuroendocrine Tumors
Introduction: Somatostatin analogues (SSA) represent one of the main therapeutic options in patients affected by functioning well-differentiated neuroendocrine tumors (NETs). There are no studies specifically focusing on NETs associated with Multiple Endocrine Neoplasia type 1 (MEN1).
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Valeria Ramundo
#1207 A Novel MEN1 Gene Variant in a Sporadic Case of Multiple Endocrine Neoplasia Type 1
Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterised by the occurrence of hyperparathyroidism, pituitary adenomas and duodeno-pancreatic neuroendocrine tumours (NETs). Germline mutations of the MEN1 gene are identified in up to 87% of MEN1 families and 82% of isolated MEN1 cases.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Donato Iacovazzo